Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS)
CNY11.98
+0.39 (+3.37%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 46, Waisha Road 318000
Taizhou, CN
Taizhou, CN
CEO
Weihong Xiao
Website
hisunpharm.com
IPO
2000-07-25
ISIN CNE0000013Z2
Description
Zhejiang Hisun Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical products. Its portfolio includes both active pharmaceutical ingredients (APIs) and finished drug formulations. The company's extensive therapeutic focus spans oncology, cardiovascular health, infectious diseases, liver support, orthopedics, parasitic infections, and immunosuppression. Additionally, Hisun Pharmaceutical addresses conditions such as weight management, viral infections, tuberculosis, and offers veterinary pharmaceuticals, among other specialized medical applications. Beyond its product lines, the firm provides product consultation and contract manufacturing/research (CMO/CRO) services. Established in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is headquartered in Taizhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY11.98
+0.39 (+3.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
24M
Beta
0.35
Float Shares
704.30M
Free Float %
58.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.08% | -3.67% | -9.45% | -1.63% | -1.91% | +3.64% | +11.05% | -16.12% | -25.45% | -8.07% | +135.63% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11.98
DCF (Unlevered)
22.40
+87.0%
DCF (Levered)
26.31
+119.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.93
Grey zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.8% ★ Q1'26: -9.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-11.5% Q1'26: +82.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+11.6% Q1'26: +13.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.7% Q1'26: +20.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.3% Q1'26: +16.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.7% Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.15× Q1'26: 0.74× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.77B
est: 9.20B (-4.7%)
|
9.73B
est: 9.63B (+1.1%)
|
10.57B
est: 9.20B (+14.9%)
|
10.19B
est: 9.63B (+5.8%)
|
11.07B
est: 11.08B (0.0%)
|
11.35B
est: 13.40B (-15.3%)
|
12.04B
est: 12.70B (-5.2%)
|
10.37B
est: 11.92B (-13.0%)
|
9.79B
est: 9.93B (-1.5%)
|
10.55B
est: 9.34B (+12.9%)
|
9.56B
9.56B – 9.56B
+2.3% YoY
|
9.85B
9.85B – 9.85B
+3.0% YoY
|
| EBITDA |
709.46M
est: 1.44B (-50.7%)
|
834.28M
est: 1.50B (-44.5%)
|
1.17B
est: 1.44B (-18.4%)
|
925.12M
est: 1.50B (-38.5%)
|
398.06M
est: 1.73B (-77.0%)
|
1.85B
est: 2.09B (-11.9%)
|
1.99B
est: 1.98B (+0.1%)
|
1.35B
est: 1.86B (-27.3%)
|
1.71B
est: 1.59B (+8.1%)
|
1.89B
est: 1.49B (+27.0%)
|
1.53B
1.53B – 1.53B
+2.3% YoY
|
1.57B
1.57B – 1.57B
+3.0% YoY
|
| EBIT |
162.21M
est: 611.17M (-73.5%)
|
228.54M
est: 639.53M (-64.3%)
|
499.63M
est: 611.17M (-18.3%)
|
180.09M
est: 639.53M (-71.8%)
|
-487.26M
est: 735.49M (-166.2%)
|
970.95M
est: 889.96M (+9.1%)
|
956.29M
est: 843.27M (+13.4%)
|
316.55M
est: 791.38M (-60.0%)
|
646.81M
est: 662.28M (-2.3%)
|
915.45M
est: 622.70M (+47.0%)
|
636.99M
636.99M – 636.99M
+2.3% YoY
|
656.36M
656.36M – 656.36M
+3.0% YoY
|
| Net Income |
13.57M
est: 404.64M (-96.6%)
|
-94.43M
est: 57.81M (-263.4%)
|
13.57M
est: 404.64M (-96.6%)
|
-492.47M
est: 57.81M (-951.9%)
|
93.07M
est: 150.30M (-38.1%)
|
417.19M
est: 184.98M (+125.5%)
|
488.86M
est: 574.59M (-14.9%)
|
-93.17M
est: -69.37M (-34.3%)
|
601.18M
est: 511.32M (+17.6%)
|
540.71M
est: 411.41M (+31.4%)
|
528.95M
528.95M – 528.95M
+28.6% YoY
|
552.46M
552.46M – 552.46M
+4.4% YoY
|
| SGA |
2.17B
est: 2.73B (-20.7%)
|
2.27B
est: 2.86B (-20.6%)
|
2.20B
est: 2.73B (-19.5%)
|
3.22B
est: 2.86B (+12.7%)
|
3.81B
est: 3.29B (+15.9%)
|
3.37B
est: 3.98B (-15.2%)
|
3.42B
est: 3.77B (-9.1%)
|
3.25B
est: 3.54B (-8.2%)
|
2.99B
est: 2.63B (+13.8%)
|
1.43B
est: 2.47B (-42.2%)
|
2.53B
2.53B – 2.53B
+2.3% YoY
|
2.60B
2.60B – 2.60B
+3.0% YoY
|
| EPS |
0.01
est: 0.35 (-97.1%)
|
-0.10
est: 0.05 (-300.0%)
|
0.01
est: 0.35 (-97.1%)
|
-0.51
est: 0.05 (-1,120.0%)
|
0.10
est: 0.13 (-25.8%)
|
0.43
est: 0.16 (+170.1%)
|
0.42
est: 0.50 (-15.5%)
|
-0.08
est: -0.06 (-33.3%)
|
0.52
est: 0.44 (+19.5%)
|
0.46
est: 0.35 (+31.4%)
|
0.45
0.45 – 0.45
+28.6% YoY
|
0.47
0.47 – 0.47
+4.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.28B
OE per share TTM
1.96
Owner's Yield
19.39%
Maintenance CapEx ratio
526.63%
Maint CapEx / Avg PPE
81.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 27 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.12% | 454.5K | 0.44% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 666.0K | 0.39% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 106.0K | 0.46% |
| 4 | Vanguard FTSE All-World UCITS ETF (USD) Distributing VWRD.L | 0.00% | 3.16M | 0.19% |
| 5 | Vanguard FTSE All-World UCITS ETF (USD) Accumulating VWRA.L | 0.00% | 3.16M | 0.19% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 12.4K | 0.44% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 172.4K | 0.29% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 85.2K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 85.2K | 0.17% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 146.6K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
113.6K
Shares Outstanding
1.20B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Shun Jin | Senior Vice President | — | male |
| Jiaqiu Du | Senior Vice President & Director | — | male |
| Ling Jiang | Senior Vice President, Accounting Supervisor & Chief Financial Officer | — | male |
| Weihong Xiao | Chief Executive Officer & Chairman | — | male |
| Xi Fei Shen | Secretary of the Board | — | male |
| Zhiqing Yang | Senior Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600267.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
